DSS Imagetech Exclusively Enables Advanced TULSA-PRO Prostate Cancer Treatment To Improve Patient Outcomes In India

DSS Imagetech is revolutionizing the prostate cancer landscape in India by exclusively bringing Canada-based Profound Medical Corporation’s TULSA-PRO system to the country, with the technology currently available at KIMS Hospitals in Hyderabad as the first and only center in India and South Asia. Announced on October 22, 2026, TULSA-PRO is an advanced, MRI-guided, radiation-free, and incision-free technology designed for the precise ablation of prostate tissue. The system delivers controlled ultrasound energy through the urethra to precisely target malignant prostate tissues while preserving surrounding unaffected structures, allowing physicians to visualize the prostate, target the treatment area precisely, and monitor the process in real time.

According to Anish Kaushal, spokesperson for TULSA-PRO and Business Head of the Medical Division at DSS Imagetech, greater awareness about advanced treatment options helps men make informed decisions that support recovery while preserving urinary continence and functional erections. Empowering clinicians for over a year with unmatched accuracy and minimal side effects, the FDA-cleared technology offers lesser complications and faster recovery times for eligible patients.